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ABSTRACT

Theranostic Nanoparticles Folic Acid-Carbon Dots-Drug(s) for Cancer
by
Godwin Kweku Babanyinah

This study aims to prepare theranostic nanoparticles (NPs) that are expected to increase cancer
diagnostics and therapeutic efficacy. We prepared the NPs constituting carbon dots (CDs) as an
imaging agent, folic acid as a targeting agent, doxorubicin (DOX), or gemcitabine (GEM) as
chemotherapy agents. The NPs include noncovalent FA-CDs-DOX, covalent CDs-FA-DOX, and
covalent FA-CDs-GEM. Through ultraviolet-visible spectroscopy, fluorescence spectroscopy,
and Fourier transform-infrared spectroscopy, the fabrication of these NPs was confirmed. It was
discovered that the high drug loading efficiency is the noncovalent series while the high drug
loading capacity is the covalent series. The in-vitro pH-dependent drug release data indicate the
NPs release more drugs at around pH 5.0 than at pH 7.4. The NPs sizes are between 2-5 nm. The
Cell viability was investigated using the Alamar Blue assay and the three NPs complexes
exhibited strong therapeutic efficacy against MDA-MB-468 breast cancer cells as compared with
CDs-drug.
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CHAPTER 1. INTRODUCTION

Cancer Treatment and Early Detection
According to a report by the world health organization, there were 18 million cases of
cancer with 9.6 million death globally in 2018. The report also indicated that one in every six
death is due to cancer, making cancer the second leading cause of death. Some of the cancer
types often diagnosed in America include lung cancer, breast cancer, prostate cancer, colorectal
cancer, and breast cancer as shown in figure 1. 1, 2

Figure 1. Global percentage estimation of new cases of all cancer in both sexes and all ages in
2018
There are several approaches to cancer treatment, such as surgical removal of cancer
tissue, chemotherapy, immunotherapy, radiotherapy, hormone therapy, and cryoablation.
Radiotherapy is one of the oldest methods in cancer treatment since the discovery of X-ray in
1895. Radiotherapy often causes side effects such as hair loss, fatigue, vomiting and nausea, and
vomiting, and infertility in both men and women. The reason is that the radioactive elements are
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used in radiotherapy, the healthy cells are affected by radiation making the radiotherapy less
specific to targeting cancer cells.3 Another method, the surgical approach, is an intervention and
prevention approach in curing individuals with cancer. However, after surgical removing cancer,
sometimes cancer relapse occurs. According to the literature, the surgical approach often leads to
the development of secondary malignant growth near the primary site of the tumor during the
process of healing. It is also accompanied by the possibility of the accelerating growth of the
remaining tumor cells. For example, it was documented that the surgical approach could lead to
an increase in the cancer cells when detached cancer cells circulate in the body fluid.4 Moreover,
it is difficult to completely remove all the cancer cells during surgical operations because the
cancer cells are not fully differentiated from healthy cells.5
The capacity for early detection of cancer in an individual is important in the treatment and
prevention of the disease. In many instances, cancer is not diagnosed until the cancer cells spread
beyond the site of origin. With the early detection of cancers at preliminary stages, there will be
a higher probability for the treatment and curing of the disease.6 Early detection has helped
improve the treatments of cancer, which in the long run significantly increased survival rates. For
cancer detection, the patients usually are screened for certain physical warning signs of the
disease. A clinical test can also be performed to diagnose the disease. There are some early
physical indications of cancer growth, including irregular bleeding, development of lumps, skin
blemishes, and non-healing wounds. Many health agencies such as the American Cancer Society,
the World Health Organization, and the Center for Disease Control educate and give
recommendations to the general public, and healthcare providers on how to detect these early
physical signs of cancer. For example, regular physical examination of the female breast for
irregularities has become a common practice recommended by the American Cancer Society to
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be conducted every three (3) years intervals for women between the age of 20 to 40 years old.7
Although the physical examination is nonconclusive to infer cancer development, it pre-informs
the individual on the next step to confirm the presence or the absence of cancer growth. The
further step in cancer detection and confirmation is through clinical screening.
Clinical screening usually provides scientific or clinical evidence of cancer or tumor growth.
Clinical screening is, therefore, an effective diagnostic technique used in cancer detection. This
involves conducting various clinical tests on an individual with or without any signs of cancer.
Clinical screening often detects cancer antibodies and cell receptors present on cancer cell
surfaces. For instance, for cervical, prostate, lung, and breast cancer diagnosis, cytological
examination, or serological test is used to detect early-stage cancer development. This screening
method mostly relies on detecting the relatively high concentration of certain cancer biomarkers
such as alpha-fetoprotein (liver cancer), and BRCA2 (breast/ovarian cancer).8 Since the
detectable biomarkers are produced in very low concentration during the early stages of cancer,
their detection by this method is almost impossible and often gives false negative. This screening
type has been used successfully in detecting cancer tumors, however, their ability to detect early
stages of cancer is limited.7, 9, 10
Another method of early cancer detection tool of clinical screening is called a wholebody scan that involves using high-energy radiation, electrons, or electromagnetic wave to
directly visualize cancer in the body. The whole-body scanning tools include magnetic resonance
imaging (MRI), X-rays, and positron emission tomography (PET). For example, mammography
is a technique using X-rays to diagnose and locate lung or breast cancer. Because of high-energy
radiation, ultrasound, and radioactive tracers, these tools pose some health risks. According to
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the America College of Preventive Medicine, these methods are also difficult to detect deep
tissue cancer cells, and costly, costing between $500 to $1,000.11,12,13
Chemical Therapy
For many years, the use of chemotherapy (chemical agents) for cancer treatment has
found grounds in recent pharmacological research. The chemical agents either inhibit the growth
and or directly kills the cancer cells, thereby stopping the growth of the tumor.14 Different
classes of cancer drugs have their unique mechanisms toward cancer cell destruction. Some
anticancer drugs can impair the DNA or RNA synthesis in cancer cells by disrupting the process
of the cancer cell division (mitosis and meiosis). Other classes of anticancer drugs block a
specific vital metabolite that is required for cancer cell survival. When the cancer cells are
deprived of their essential metabolite and cannot divide, they can no longer spread and
eventually die. The anticancer drug also can be administered singularly or in combination with
another. One of the typical classifications of cancer drugs is based on their working mechanism
is shown in figure 2. Anticancer drugs usually are given to patients orally or intravenously.
However, most cancer drugs are non-specific for cancer cells. Most anticancer drugs harm both
the cancerous and the healthy cells which often leads to serious side effects. Such side-effects
include; anemia, diarrhea, nausea and vomiting, and hair loss. This has become one of the main
challenges in cancer chemotherapy. Chemotherapy has, therefore, not been able to reach its full
potential. 5,15,16
The upsurge in cancer chemotherapy research is incited by finding solutions to this and
other drawbacks pertaining to chemotherapy. The challenges facing many anticancer drugs
needed to be resolved include drug selectivity, drug distribution, drug resistance, and drug
solubility. Improving these areas of drug pharmacokinetic is reported to help enhance the cancer
14

drug circulation, distribution, release rate to the cancer site. The research into the drug delivery
system (DDS) and its application in cancer chemotherapy have been explored widely.

Figure 2. Classification of anticancer agents

Nanosized Drug Delivery System for Chemical Therapy
One of the main challenges in chemical therapy is to control release and site-specific
delivering anticancer drugs. One way to resolve this drawback to achieve a higher therapeutic
effect of administered chemical agents is by using delivering agents, also known as drug delivery
systems (DDS). The use of DDS in therapy is known to improve the overall drug profile; biodistribution, drug release, drug absorption, and elimination. This improvement is noted to
increase the therapeutic benefits of drugs.
Among the different types of DDS, the nanosized DDS are known to significantly
enhance the diffusion of the loaded drug into the specific cancer cells. With the sizes less than
15

100 nm, the nanosized DDS is easier to load drugs and aid them to cross tissue barriers. This
improves the drug therapeutic efficiency since the overall cellular uptake is enhanced.17 Some
common types of NPs DDS include liposomes, polymeric micelle, dendrimers, and mesoporous
silica nanoparticles.
Nanosized-based DDS in cancer therapy is documented to overcome drug resistance.
Drug efflux pumps on cancer cells are reported to participate in anticancer drug resistance by
cancer cells. Free anticancer drugs are usually internalized through diffusion across the cell
membrane. The drug efflux pumps present on many cancer cells membrane can detect the free
anti-cancer drug and prevent them from getting into the cancer cell. According to Kibria Et al., to
increase the drug efficacy, nanosized-based DDS can be a powerful tool where the drug can be
loaded for delivery. This is because the nanosized-based DDS can cross the cell membrane
using a non-specific endocytosis route that is undetectable by the efflux pumps resulting in a
higher accumulation of the loaded anticancer drug with the cancer cells. 18,19,20
With the DDS, the therapeutic agent can be transported to the specific tissue site of
action. This enables the drug to selectively interact with the cancer cells. Therefore, it alleviates
some of the drug’s side effects since the drug will not interact with the healthy tissues in the
cancer microenvironment. Moreover, some specific DDS can keep the drug stable and prevent
biodegradation or drug clearance from the body. Most importantly, the DDS can dramatically
increase the drug effective concentration at the sites lowers the required dosage of drugs.
Therefore, it results in low cytotoxicity and fewer side effects. 5, 21 22 17 Table 1 summarizes the
different types of DDS used in cancer research. 23 24 The DDS includes polymers, transition
metals, and carbon-based materials. Their advantages and disadvantages are as well summarized.
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The method of loading the drug onto the DDS is very important as it affects the loading capacity,
loading efficiency, and drug release of the DDS.
Table 1. Types of NPs DDS: Examples, Advantages, and Disadvantages
Type of DDS

Polymer

Examples

Advantages & disadvantages

Liposomes

It is biocompatible.

Micelles

Nontoxic.

Dendrimers

Have a relatively larger particle size.

Microsphere

Metal base

Au NP

Photo-fluorescence

Palladium NP

Bio-incompatible

Platinum NP

High toxicity

Iron Oxide NP
Nano-diamond
Carbon base

Biocompatible

Carbon nanotube
Graphene oxide
Carbon dots

Typically, the therapeutic agent(s) is chemically or physically attached to DDS. Physical
attachment such as encapsulation is especially advantageous for targeting cancer cells. The lipidmediated DDS with an encapsulated drug is reported to enhance the affinity of the drug with the
cancer cell. Also, the common non-covalent bond observed between the drugs and DDS
includes π-π interaction, hydrogen bonding, electrostatic, hydrophobic, and steric
immobilization. This form of attachment results in the easy release of the loaded drug. However,
the non-covalent interaction to those DDS can lead to comparably low drug loading content and
efficiency.25 Covalent bonding, usually involves the structural changes of the DDS and the
17

loaded drug to form the actual chemical bond such as the amide bond. With covalent attachment,
the drug loading capacity and efficiency of the DDS is enhanced. Moreover, the covalent
attachment of drugs to DDS makes it flexible to control the concentration of the drugs loaded
onto the DDS. Nevertheless, it becomes difficult for the drug to be released once attached to the
DDS.25, 26,19, 27
Polymer NPs DDS is generally reported to be less or non-toxic and highly biocompatible.
Nevertheless, many polymeric NPs used as DDS are reported to respond slowly to stimuli
relative to other types of NPs. These stimuli comprise light, pH, and temperature. Since these
stimuli are not specific to any organ or tissue in the body there is no specificity in the release
drugs. 23 Moreover, the rather large size of many polymeric NPs DDS poses problems such as
poor stability, absorption, bioavailability, and clearance. All these limits their biomedical
applications.
Metal NPs DDS in cancer chemotherapy has also been developed in cancer-related
research. Examples of the metal base NPs are; Au, Rh, Ir, and Pd.24 Metal-based NPs are chosen
because of their large surface area, broad optical properties, easily functionalized with different
chemical groups. Nevertheless, these NPs as DDS are also limited in their application in
biomedical research. Metal-based NPs are reported to have high cellular toxicity and short-lived
photoluminescence for bioimaging. Depending on the metal and how the NPs are made, it is
usually very simple and often required that the NP will have functional groups. Bare metal
nanoparticles are often difficult or impossible to prepare as a suspension because capping agents
are often required for a successful bottom-up approach. This, therefore, limit their drug loading
capacity. 28 Hence, considerable biomedical research is shifted toward finding alternative NPs
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DDS that have less cellular toxicity, high biocompatibility, more flexibility for chemical
functionalization, and free of heavy metal.
One of the most common NPs DDS that has attracted attention is carbon-based NPs due
to their inherent characteristics such as excellent water solubility, high photostability, chemical
inertness, and long lifetime emission. The typical examples of the carbon-based NPs DDS are
single or multi-walled carbon nanotubes, graphite, fullerene, nano-diamond, and carbon dots.14
Quantum Dots
Quantum dots (QDs) are inorganic nanocrystal semiconductors with a dimension of about
2 to 10 nm that contain approximately 100 to 10, 000 atoms per individual particle. Because
QDs have high electron density in their valence band, these electrons can be excited from the
valence band to the conduction band. This excitation is triggered by the absorption of radiation.
Relaxation of these excited electrons coincides with the emission of visible light, endowing the
QDs with fluorescence activities. QDs are applicable in bioimaging because QDs offer nearinfrared emissions that is rare in organic dyes. Since cells can also absorb UV-light and produce
background emission leading to poor contrast during bioimaging, near-infrared sensitive
materials like QDs are, therefore, a good alternative to explore.29 The optical properties and the
electronic properties of QDs depend on the NP composition and size. Due to their high quantum
yield and excellent photoluminescence, QDs have been exploited in imaging and as optical
sensors such as in cancer research. Some common examples of metals used in producing QDs
include; selenium, zinc, tellurium, and cadmium. 30,31
Metal-based QDs have undesirable properties making their bio-applications limited. For
instance, metal Cd2+-based QDs can aggregate to membrane structures such as mitochondrion,
and DNA to induce oxidative stress. The Cd2+ also binds with sulfhydryl of proteins to cause
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severe cytotoxicity. Cadmium-based QDs is also reported to be toxic to vertebrate even at low
concentrations. 29,30,31
Even though silicon and germanium, belong to the same group in the periodic table as
carbon, carbon-based QDs (also called carbon dots) provide a more effective solution in the
development of alternative QDs with wide bio-application. This explains why carbon-based
QDs has gained much attention in biomedical applications such as bioimaging.32,28
Carbon Dots
Carbon dots (CDs) is carbon base nanomaterials, that can be classified under quantum
dots because of its smaller particle sizes, semi-conductivity, zero-dimension, high photostability,
tunable emission, and large two-photon excitation cross-sections. CDs have some exceptional
properties such as non-blinking fluorescence, high solubility that make their application feasible
in bioimaging research. CDs typically have particle diameters between 2nm to10 nm.33, 34 They
are very small carbon nanoparticles with comparatively intense fluorescent activity over a wide
range of wavelengths.35,36,37,38
Moreover, CDs can be functionalized by various chemical groups on their surface. Most
significantly, CDs are more environmentally friendly than other NP-based DDS materials. CDs
have been widely used in optical, biological, environmental, and energy-related research as
shown in figure 3. 14, 39 Besides these properties, CDs also have inherent medicinal properties as
inhibitors of insulin fibrillation and the suppressors of cancer cells including MCR-7 cancer cells
lines and breast cancer cells lines (MDA-MB-231). This observed cancer inhibition is attributed
to the formation of a large amounts of reactive oxygen species.40,41

20

Figure 3. Different applications of Carbon Dots

Carbon Dots as DDS
CDs are among the top candidate in designing new NP-based DDS. With their small
sizes, inertness, and excellent water solubility, CDs can easily be absorbed by the kidney in order
to pass out via the urine. It is therefore easier to clear the CDs out of the body. That is, the
accumulation leading to cytotoxicity is prevented. Functional groups include COOH, OH, and
NH2 on the CDs surface can be further modified for other conjugation. In research where CDs
were used as a DDS, doxorubicin (DOX) was successfully conjugated onto CDs with a high drug
loading capacity. In the cytotoxicity assay test, the IC50 values were found more effective than
the drug alone against the MCF-7 cancer cell line. The CDs-DOX complex was reported to have
a lower IC50 compared to the free DOX. This proves that the CDs can be used as a delivery
system for anticancer drugs to achieve better anticancer therapy than a standalone anticancer
drug. 36
21

Yu Et al. also reported the new folate (L-5-methyltetrahydrofolate) reducible
polyethyleneimine CDs (fc-rPEI- CDs) which show visible blue photoluminescence at 360 nm
excitation. In their study, the CDs conjugated with the fc-rPEI complex were used as the siRNA
gene carrier to deliver the gene into the lung cancer cells. The study indicated that the fc-rPEI –
CDs siRNAs complex is selectively accumulated in lung cancer cells via receptor-mediated
endocytosis, for effective gene silencing and cancer treatment effect. It was reported that the NP
complex still maintains its blue fluorescence even after ten days. 35 The integrated theranostic NP
complex provides a valuable tool to benefit clinicians in adjusting therapeutic strategy and drug
dosage in real-time response by monitoring and tracking the cancer development. 42
CDs for Cancer Cell Detection
The use of CDs as an imaging agent has attracted lots of interest in cancer
research.43,44,45,35 Due to the quantum confinement effect, the nanoscaled CDs inherit special
optical properties. As the size of CDs reduces, the electron energy bandgap between the valence
and conduction band increases. It leads to several fluorescent colors reflecting the small
differences in the CDs size. Other properties such as biocompatibility, easily functionalized
surface, and the chemical inertness of CDs make them a good option for bioimaging and bio
labeling agent compared to the inorganic quantum dots. 28 46,47
For example, Zheng and his coworkers reported that the prepared CDs act as a
fluorescence imaging and targeting agent for noninvasive brain cancer glioma diagnosis. 48 In the
report, the fluorescence images showed that the CDs conjugated to aspartic acid (CDs-Asp) had
high contrast biodistribution of CD-Asp even after 15 min of intravenous injection. It proved that
the prepared CDs-Asp has both bioimaging and glioma cell targeting properties. On the right, a
stronger fluorescent signal was observed in the glioma site than that in the normal rat brain. This
22

also indicated the ability of CDs to freely pernitrate the blood-brain barrier and detect cancer
cells in the brain (glioma cells). That is, CDs-Asp has high selectivity for the brain C6 glioma
cells.48
Carbon Dots Synthesis
The synthesis of CDs is grouped into two main approaches. They are top-down and
bottom-up. A top-down approach in CDs synthesis involved the breakdown of large carbon
macromolecules including graphene, nano-diamond, and carbon nanotube to form the CDs. In
the latter approach, the CDs is synthesized from the accumulating tiny carbon-containing
materials such as ethylene, glycol, and citrates. The top-down approach includes the following
method: laser ablation, chemical ablation, and electrochemical synthesis. The bottom-up involve;
pyrosis, hydrothermal, microwave-assisted synthesis. 49,50 Table 2 is the summary of the various
techniques reported on the synthesis of CDs. 28,51,52
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Table 2. Carbon Dots Synthetic Approach
Method
Laser ablation

Size/n Quantum Yield
m
(QY)%
5

Advantages

Disadvantage

Most attainable

Harsh condition and
low QY

Electrochemica
l
6-8

4 - 10

Simple

poor control of size

Thermal

0.1 - 8.9

Simple

Low QY

3 - 21

Simple and less
expensive

Poor control of size

>50

Simple, highly watersoluble

poor control of size

Colloidal stability

Expensive method

Microwaveassisted
Hydrothermal
Template

2-6
4.5

Among all these methods, the hydrothermal treatment also known as solvothermal
carbonization is of great interest for our research. This is because, the method is a low-cost,
simple, ecofriendly, and non-toxic path to produce CDs. This process involves just one step
reaction making it the simplest among all the methods. Depending on the precursor used in the
synthesis the fluorescence quantum yield (QY) varies. For example, sulfur-doped CDs from
cysteine under the hydrothermal method has a QY of 94.5%.53
Target Agent
One of the common methods to improve the specificity of the drug is by using a target
agent. The non-specificity of the many anticancer drugs to the cancer site(s) leads to a low
therapeutic effect. When a target agent is attached either directly to the drug or the drug-DDS
complex, the conjugate can then specifically bind to its complementary cellular receptor. This
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specific binding aided by the target agent help improve the overall cell specificity and increase
the drug uptake by the target cells. 49 This will help reduce the toxic effect of the attached drug
on neighboring healthy cells and further minimize the side effects of the administered drug.54
The target agents used for cancer identification depend on the type of cancer cell receptor
expressed by the cancer cells. The use of a target agent in cancer chemotherapy is reported to
enhance the selectivity of cancer drugs.55, 29
The type of receptor on the cancer cell determines which target agent will be used.
Ligand-based targeting receptor is by far the most highly used in cancer research. Examples of
the ligand-based targeting receptors include; human epidermal growth factor receptor-2 (HER2),
epidermal growth factor receptor (EGFR), transferrin receptor (TfR), and prostate-specific
membrane antigen (PSMA), carbonic anhydrase IX, biotin receptors, and folate receptor (FR).
53,54

It is therefore significant to select the best target agent for effective drug therapy. To choose

the match target agent for the drug(s), the requirement are that; 1)high affinity of the target agent
to the receptor of cancer cells; 2) the receptor should have a high expression on the cancer cell
than on healthy cell, for example, folate targets FR which is overexpressed on many cancer
cells.56,57
Folic Acid
In this current research, folic acid (FA) is selected as the target agent to help deliver
anticancer drugs and as the imaging agents. FA is highly biocompatible, nontoxic, stable,
biodegradable, and can be used as a DDs. FA is an essential artificial food additive added to food
to supplement folate loss during food processing. FA is essential because it is required in the
body to synthesize purine and pyrimidine needed to build and repair nucleotides. FA is watersoluble and has high bioavailability than naturally occurring folate. 58 FA is reported to target the
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folate receptor that is present on many tumor cells. The structure of the FA is represented in
figure 4. Human cancers such as breast cancer, lung cancer, and prostate cancer are known to
have the alpha Folate Receptor (FR-α) which is overexpressed on their cell surface. The FR-α
has a high affinity for folate and it reduced form-folic acid. For instance, HeLa cells are cervical
cancer cell line that has overexpressed FR on its cell membrane. When the HeLa cell line was
incubated with the FA-CDs complex, it was found that the CDs readily permeated the cancer
cells and gave a measurable fluorescence signal. A comparable low level of fluorescence was
observed when only CDs are used. In another set-up, when the A549 cell line (cell line with
deficient FR on its cell membrane) was used, there was a very low level of fluorescence
observed in both the control and FA-CDs complex. It demonstrates that the use of FA can
effectively target FR-positive cancer cells. 53,54

Figure 4. The structure of folic acid
Cocktail Chemotherapy
One of the main drawbacks of cancer chemotherapy is cancer drug resistance, and the
struggle to develop novel anticancer drugs. New drug discovery is costly, and it takes about 15
years for a single cancer drug to be approved. The constraint in time and the cost of developing a
new anticancer drug can be minimized by exploring cancer combination chemotherapy.59
26

Besides, due to the physiological complexity of cancer tumors, the use of single anticancer drug
therapy may not be enough for effective chemotherapy. Therefore, combination chemotherapy
also called cocktail anticancer drug might be an effective approach for modern cancer
chemotherapy.20
Cocktail or combination chemotherapy involves the simultaneous use of two or more
chemotherapeutic agents often with a different mechanism of action to better kill cancer cells.
This approach in chemotherapy is gaining momentum in cancer drug-related research. Unlike
single-drug chemotherapy where the drug has one signaling pathway, a cocktail anticancer drug
can use different cancer cell signaling pathways. That is the use of cocktail drug systems can
drastically increase the overall therapeutic efficacy through additive effects, synergistic effects,
and potentiation effects.60 Since the use of nanosized DDS is documented to help increase the
therapeutic effect of a single anticancer drug, loading multiple drugs onto nanosized DDS may
increase the effective therapy of the cocktail drug in multiple folds.20
Jack and Zhang20 reported that when DOX and cyclosporin-A were co-loaded on
polyalkylcyanoacrylate (CYA) nanoparticles against DOX resistant leukemia cell line, there was
about a two-fold increase in the leukemia cell death. Cancer cell apoptosis was dramatically
increased when nanoparticle-DOX -CYA was used as compared to standalone DOX. Therefore
the use of cocktail anticancer drug and nanosized DDS could be a powerful tool to improve
cancer chemotherapy by overcoming anticancer drug resistance.20,61
Doxorubicin (DOX)
Doxorubicin is one of the frequently used anthracycline anticancer drugs sold under the
trade name Adriamycin. DOX is one of the commonly prescribed anticancer drugs as first-line
chemotherapy in clinics. The precise DOX mechanism of action on cells remains unclear. For

27

instance, it is reported that DOX increases the free oxygen radicals which cause oxidative stress
results, such as DNA damage, senescence, and cell death.62 Another reported mechanism is
through the destruction of the mitochondrial membrane in the cell leading to cell death. 63
DOX is also reported to inhibit the topoisomerase II enzyme, which usually is responsible
for DNA opening and supercoiling. The inhibition of this enzyme leads to the cessation of cell
proliferation.18 DOX is a first-line treatment prescribed against various types of cancers such as
leukemias, breast cancer, lymphomas, sarcoma, and lung cancer. Like many other cancer drugs,
DOX has some drawbacks, such as non-specificity and somatic cellular toxicity. Other side
effects associated with DOX include nausea and vomiting, diarrhea, loss of appetite, missed
menstrual period, darkening of your skin or nails, weakness, tiredness, and eye redness. Another
problem of DOX is its low affinity for nuclei and limited diffusion into cells.64,15,45 The several
functional groups present on DOX figure 5), such as -OH and, NH2, increase the possibility to
attach the drug to either DDS or target agent or both.

Figure 5. Structure of DOX

Gemcitabine (GEM)
Gemcitabine is one of the first-line anticancer pro-drug commercially known as GEM,
which is classified as an antimetabolite.65 It is one of the standard cancer drugs administered
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intravenously to treat pancreatic cancer. GEM is proven to have a wide spectrum of anticancer
activity and can help treat breast cancer, ovarian cancer, non-small lung cancer, and bladder
cancer.66,67,68,69 The GEM is a deoxycytidine nucleoside analog with two fluorine atoms (figure
6). The presence of the chemical group such as -NH2 and -OH makes it possible to attach this
drug to other compounds.
The diphosphate and triphosphate of GEM are reported with anticancer activity.65 For
instance, GEM-diphosphate is proven to inhibit ribonucleotide reductase (RNR). Ribonucleotide
RNR is important in the synthesis of new DNA nucleotides. The triphosphate GEM can
competitively incorporate into new DNA as a false nucleotide during cell division. This false
nucleotide becomes unrecognizable and irreparable by the DNA repair system. This therefore
destructs and terminates DNA chain elongation. This eventually leads to premature cell
apoptosis and termination of cell division. GEM is therefore classified as an antimetabolite
anticancer drug.
Since GEM targets tissues with high cellular division, it turns to affect other healthy cells
that are undergoing regular cell division.67,70,69 That is, GEM face a challenge of non-specificity
leading to many side effects.68 Some common side effects include; joint pain, weakness,
numbness diarrhea, dizziness, fever, bone marrow toxicity, and weight loss. Moreover, the
hydrophobicity of GEM makes it difficult for the drug to cross the lipid bilayer of cells. This
decreases the effective concentration of GEM in the cells.
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Figure 6. Structure of GEM
Research Plan
The primary goal of this study is to prepare novel CDs based nanoparticles as potential
theragnostic for cancer treatment. The NPs complex will comprise of CDs, folic acid (FA) as the
target agent, and anti-cancer drug DOX or GEM. Previous work in my research group
successfully synthesizes and characterized two series of carbon dots from citric acid and
ethylenediamine. DOX was successfully attached to the two series of carbon dot-folic acid
complexes via non-covalent linkage. The CDs-DOX and FA-CDs-DOX were also characterized.
It was found that the CDs series B (with 1:1 citric acid to ethylenediamine) gave better
fluorescence and had higher drug content. However, information on drug load content, drug load
efficiency, and the NPs toxicity of these complexes from covalent synthesis is limited and is,
therefore, the main aim of this current research. Four primary objectives form the basis of this
work.
1. Changing the ratio of CDs to DOX to find the best ratio to give a high drug profile (drug
load content and efficiency) by using noncovalent synthesis, and to determine the pHdependent DOX releases.
30

2. New series of carbon dots/drug-folic acid complex by exploiting the EDC carbodiimide
coupling reaction to form covalent bonding. The anticancer drugs DOX, and GEM will
be compared. The drug load efficiency and drug load content will also be determined.
The complexes synthesized will be characterized by UV-vis, FTIR for functional groups,
and fluorescence.
3. All the prepared FA-CDs- drug complex via covalent/noncovalent bonding will be tested
on cancer cell lines to assess perimeters such as cell viability, and IC50.
4. Loading both DOX and GEM on the CDs and further characterization.
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CHAPTER 2. EXPERIMENTAL

General Material
Ethylenediamine, citric acid, Gemcitabine hydrochloride (GEM.HCl), Doxorubicin
hydrochloride (DOX•HCl) was purchased from Oakwood Chemicals, two types of dialysis tubes
with pore size with molecular weight cut-off of 1.0 KDa and 3.5 KDa, 3-(3Dimethylaminopropyl)-1-ethyl-carbodiimide (EDC), N-Hydroxy-succinimide (NHS), folic acid
(FA), gibco phosphate-buffered Saline (PBS), pH 7.4 (1X) purchased from Fischer scientific.
Synthesis of CDs
In a general method of CDs synthesis, 1.051g (10.41 mmol) of citric acid was dissolved
in 335.0 µL (0.9540 mmol, the ratio is 1:1.1) of ethylenediamine in 10 mL D.I water. The
solution was then autoclaved in a Teflon-lined hydrothermal autoclave at 250 oC for 5 hours. To
maintain the CDs size consistency, the cooled brown solution was dialyzed using a dialysis bag
with a 3.5 KDa cutoff against 500 mL D.I. water for 6 hours. It was then freeze-dried to obtain a
brown powered sample. This method was followed as reported by Schneider Et al.71 and Zhu Et
al.33 with slight modification.

Scheme 1. Hydrothermal synthesis of CDs. The insert picture for CDs showed a brilliant blue
solution under UV light
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Synthesis of Non-covalent CDs-DOX from DOX.HCl
In a general method, 4.00 mg of the CDs was dissolved into 1.00 mL DI water. This
solution was sonicated for 15 minutes. To this solution, 1.00 mL of 0.4 mg/mL DOX.HCl
(6.89x10-4 mmol/mL, the weight ratio of 1:10) was added and 2.00 mL of 1 X PBS was added to
the final mixture. This mixture was then transferred into a 20 mL round-bottomed flask and
covered with aluminum foil to prevent photo-degradation. The mixture was stirred at room
temperature for 24 hours. The volume of the solution after synthesis was 3.9 ml. 0.2 ml of
solution was diluted into 1 ml aqueous solution with D.I water for UV-analysis. The rest of the
CDs-DOX was dialyzed with a 1 KDa dialysis tube against 500 ml D.I. to obtain 3.7 mL of
solution. From this solution, 0.2 ml was diluted into 1 ml aqueous solution with 1ml D.I water
for UV-analysis. CDs-DOX was prepared by a slight modification of the procedure by Yuan
Et.al.15
Synthesis of Non-covalent FA-CDs-DOX from DOX.HCl
In a general method described by Yuan Et al.15, 1.50 mL of FA-CDs (8 mg/mL) was first
sonicated for 15 minutes, and then 1.50 mL of 0.4 mg/mL DOX.HCl (1.0345 µmol) was added.
The solution was kept under a stirring condition of 200 rpm at 25 ºC in the dark (to prevent
photo-degradation of DOX) for 24 hours. The volume of the solution was 3.9 ml. 0.2 ml of the
solution was diluted into 1 ml aqueous solution for UV-vis analysis. The rest of the 3.7 ml FACDs-DOX solution was dialyzed in a 3.5 KDa dialysis tube against 500 ml D.I water for two (2)
hours to obtain a 3.8 ml final product. The volume of the FA-CDs-DOX solution after dialysis
was 3.8ml.
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Synthesis of Covalent CDs-DOX or CDs-GEM from DOX.HCl or GEM.HCl
In a general procedure, the prepared CDs (4 mg) was dissolved in 1.5 mL phosphatebuffered solution (PBS, pH 7.4) and sonicated for 15 minutes. To this solution, 0.5 ml of
17mg/ml 1-ethyl-3-(3-dimethylamino propyl) carbodiimide hydrochloric acid (44.3 µMol
EDC.HCl) was added and stirred for 30 minutes. Then, 0.5 ml of 10.2 mg/ml N-hydroxy
succinimide (44.3 µMol NHS) was also added and stirred for another 30 minutes. The ratio of
the EDC to NHS was maintained at 1:1 in the synthesis. After that, 0.5 ml of 5 mg/ml (8.3 µMol)
DOX.HCl was added and stirred overnight in the dark to prevent the photodegradation of the
DOX.HCl. The overall ratio of the DOX to EDC or NHS was 1:5.3. The final solution was
dialyzed against 1 L of D.I water with a 3.5 kDa dialysis tube. The dialysis was carried out for 4
days with the dialysate medium changed every 24 hours. The final solution was lyophilized to
obtain brownish solid CDs-DOX72 for FTIR analysis. The process was repeated with GEM with
a molar equivalent to DOX. That is, 0.5 ml 5mg/ml (8.3 µMol) of the GEM was added in replace
of the DOX to synthesize the covalent CDs-GEM. All molar ratios were maintained.
Synthesis of Covalent FA-CDs-DOX or FA-CDs-GEM From DOX.HCl or GEM.HCl
In this procedure, CDs (4 mg) was dissolved in a 1.5 mL phosphate-buffered solution
(PBS, pH 7.4) and sonicated for 15 minutes. To this solution, 0.5 ml 17 mg/ml 1-ethyl-3-(3dimethylamino propyl) carbodiimide hydrochloric acid (44.3 µMol EDC.HCl) was added and
stirred for 30 minutes. Then, 0.5 ml of 10.2 mg/ml N-hydroxy succinimide (44.3 µMol NHS)
was also added and stirred for another 30 minutes. The ratio of the EDC to NHS was kept at 1:1
in the synthesis. Next, 0.5 ml of 5 mg/ml (8.3 µMol) DOX.HCl was added and stirred overnight
in the dark to prevent the breakdown of the DOX.HCl by light (DOX.HCl is photosensitive). To
this solution, 0.13 ml of 0.1 mg/ml folic acid (FA) was added and stirred overnight in the dark.
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The ratio of the DOX to the FA was 280:1. The final solution was dialyzed against 1.0 L of D.I
water with a 3.5 KDa size cutoff point for 4 days. The dialysis medium was changed every 24
hours to ensure complete removal of unreacted CDs, NHS, EDC, and DOX. The dialysis setup
was kept in the dark to prevent the breakdown of DOX. UV-vis analysis was done before and
after dialysis. The final solution was lyophilized to obtain brownish solid FA-CDs-DOX for
FTIR analysis. The process was repeated with GEM with a molar equivalent to DOX. That is,
0.5 ml 5mg/ml (8.3 µMol) of the GEM was added in replace of the DOX to synthesize the
covalent CDs-GEM. All molar ratios were maintained. This procedure was followed with a small
modification to the method documented by Liyanage at al.72

Scheme 2.EDC/NHS coupling reaction
Spectroscopy
The UV-vis properties of the absorption of the samples and intermediates were recorded
with PharmaSpec UV-1700 PerkinElmer ultraviolet-visible UV-vis spectrophotometer in a 1 cm
quartz cuvette. 0.01mg/ml of the solution was prepared and scanned from 190 nm to 600 nm to
capture all peaks present in the samples and intermediates.
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The fluorescence emission spectra measurements were taken with the FluoroMax-3
spectrophotometer. About 1.5 ml of the aqueous solution of the nanoparticle was transferred into
a 1cm quartz cuvette for analysis. In the fluorescence analysis, excitation-dependency properties
of the samples were determined by exciting the sample with a different wavelength from 300 nm
to 390 nm (Monochromators having Xenon arc lamp) with 10nm increment. All samples were
scanned from 400 nm to 700 nm with a 10 nm increment.
The functional groups present on the nanoparticles were recorded using a Shimadzu
IRPrestige FTIR with ATR accessory. The solid nanoparticle after lyophilization was scanned
from 4000 cm-1 to 450 cm-1.
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CHAPTER 3. RESULTS AND DISCUSSION

Synthesis of CDs
In this research, the synthesis of CDs was done using a single-step hydrothermal
treatment of citric acid and ethylenediamine. Citric acid is an important compound that is
commonly found in food and food supplements.73 In the synthesis of the CDs, citric acid
represents the carbon source and ethylenediamine as the nitrogen source. Ethylenediamine is also
commonly used as a surfactant to enhance the bioactivity of drugs such as aminophylline.74
During the synthesis, the preferred molar concentration ratio of citric acid to ethylenediamine
was kept at 1:1.1. In previous studies, this ratio had a better and consistent drug loading profile
according to the previous work done by Dada.75 Also, as Zhu Et al.33 reported, CDs produced
from this ratio is easy for TEM imaging because this ratio produces CDs with uniform dispersion
without any apparent aggregation of the NPs. The CDs solution was dark brown which according
to Pandey Et al.76 indicated the presence of CDs. The dialysis of the CDs solution ensures
consistency in the CDs NPs size and produces CDs devoid of any by-products on its surface.
After the purification and subsequent lyophilization, the CDs yield was approximately 30 %.
This low yield might be a result of the loss of CDs during the dialysis procedure. The particle
size of the CDs was around 3-5 nm determined by dynamic light scattering, DLS.
Covalent Synthesis of CDs-DOX/CDs-GEM Complexes
The covalent synthesis of the CDs-DOX/CDs-GEM complex was completed using the
EDC/NHS coupling reaction reported by Liyanage Et al. with slight modification.72 The
carboxylic group on the surface of the CDs was conjugated with the amino group in the
DOX/GEM. This coupling reaction allows for the formation of a non-cleavable amide bond
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between the CDs and DOX/GEM. In the procedure, the EDC activates the carboxylic acid
groups on the CDs to form the O-acylisourea intermediate. The O-acylisourea intermediate is
often unstable in an aqueous medium and is therefore stabilized by the NHS to allow for
nucleophilic attack by the amino groups on DOX/GEM to form the amide bond by displacing the
EDC as shown in scheme 2.77 The unreacted reagents were washed off via dialysis to obtain the
CDs-DOX/GEM complex. The quantity of DOX was calculated using the λmax of DOX at 485
nm referring to the UV-vis standard calibration curve (figure 7) where was various
concentrations of DOX solutions were plotted against absorbance. While in the case of the GEM
complex, the concentration of the bonded GEM at λmax of 269 nm was calculated from the GEM
standard curve (figure 8).
Synthesis Covalent of FA-CDs-DOX / FA-CDs-GEM Complexes
The covalent synthesis of the FA-CDs-DOX/FA-CDs-GEM complex was completed
using EDC/NHS coupling reaction.72 The carboxylic group on the CDs surface was conjugated
with the amino group in the DOX/GEM. To this solution, the folic acid was electrostatically
added to form the covalent FA-CDs-DOX/ FA-CDs-GEM complex. The unreacted reagents such
as free DOX/GEM, CDs, FA, EDC, and the NHS were washed off via dialysis to obtain the
covalent FA-CDs-DOX/ FA-CDs-GEM complex. The average diameter of covalent FA-CDsDOX is 1.74 nm, which is smaller than the FA-CDs-GEM complex. For the FA-CDs-GEM, the
quantity of the bonded GEM at λmax of 269 nm was calculated from the GEM calibration curve.
The average diameter of covalent FA-CDs-GEM is 3.57 nm.
Calibration Curve for DOX
The concentrations of DOX present in DOX NPs complexes were determined using the
standard calibration curve in figure 7. Different concentrations of DOX were prepared and the UV
38

absorbance of the DOX for each serial concentration was recorded at 485 nm. DOX standard graph
was plotted with concentration against absorbance. The unknown concentration of the DOX from
each complex produced was calculated from the DOX standard plot equation given by y = 20.676x
– 0.0237.
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y = 20.676x - 0.0237
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Figure 7. Calibration curve of pure DOX

Calibration Curve for GEM
The concentrations of GEM present in the complexes were determined using the standard
calibration curve in figure 8. Different concentrations of GEM.HCl was prepared in DI water. The
absorbance of the different concentrations of the GEM at a maximum peak of 269 nm was taken
and plotted against the concentration to obtain the standard calibration curve.78 ,79
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Absorbance at 269 nm
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Figure 8. Standard curve of GEM.HCl showing concentration (in mg/mL) against absorbance at
269 nm
Drug Load Content (DLC) and Drug Load Efficiency (DLE)
In a general procedure, DLC and DLE were determined using the method as described by
Gao Et al.80 with slight modifications. After the synthesis of the complex, the unbounded drug
was determined to calculate the DLE and DLC. 0.2 ml of the complex after the synthesis was
diluted with 5 ml D.I water for UV-vis analysis. The maximum UV absorption peak of the
unbounded DOX at 485 nm was recorded. For the GEM, the absorbance of the free GEM at 269
nm was also recorded. The corresponding concentration of the free drug using their respective
linear equation. The difference between the free drug and the initial amount of the drug was
determined. This difference corresponds to the amount of the drug in conjugation. The DLC and
DLE were then calculated using equation 1 and 2 respectively.37 The drug load profile for the
complexes is summarized in table 3.
𝐷𝐿𝐶 (%) =

𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑖𝑜𝑛
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑡ℎ𝑒 𝐶𝐷𝑠

𝑥 100%
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Equation 1

𝐷𝐿𝐸 (%) =

𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑖𝑛 𝑐𝑜𝑛𝑗𝑢𝑔𝑎𝑡𝑖𝑜𝑛
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑡ℎ𝑒 𝐷𝑜𝑥

𝑥 100%

Equation 2

Table 3. Drug Load Profile for Covalent and Noncovalent Complexes

Covalent

Noncovalent

NPs

DLE%

DLC%

DLE%

DLC%

FA-CDs-DOX

71

80

83.8

3.9

CDs-DOX

53.7

60.9

75

7.03

FA-CDs-GEM

69.6

37.8

CDs-GEM

75.1

46.9

UV-vis Analysis of Nanoparticles
The most common optical characterization study of CDs is UV-vis analysis. The CDs
solution was scanned in a broad wavelength from 900 nm to 190 nm in the UV-vis analysis. The
CDs displayed strong and distinct absorption peaks from 200 nm to 400 nm specifically at 198
nm, 240 nm, and 344 nm as shown in figure 9. These peaks are consistent with literature
data.4,3,37 The peak at 198 nm represents π → π* electron transition in C=C bonds while that of
240 nm peak is n→π* electron transition. Also, the peak at 344 nm is attributed to the C=O and
C-N bonds with electron transition at n→π* transition in sp2 hybridization of carbonyl groups on
CDs surface.37,34,81,64,33
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Figure 9. UV-vis of 0.01mg/ml CDs showing the peaks 198 nm, 240 nm, and 344 nm.
The insert is a photograph of water (A) and CDs (B) under handheld UV-light.
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Figure 10. UV-vis of 0.01 mg/ml CDs-DOX, FA-CDs-DOX, and DOX.
The insert shows fluorescence spectra of the pure CDs, DOX, CDs-DOX, and FA-CDs-DOX
excited at 360 nm

The covalent FA-CDs-DOX and CDs-DOX complexes in figure 10 exhibited the main
UV-vis absorption peaks of CDs and DOX. In the covalent FA-CDs-DOX, the characteristic
peaks are at 201 nm, 235 nm, and 340 nm. Among them, there is a blue shift from 198 nm to 201
nm, and a redshift from 240 nm to 235 nm. Similar characteristic peak shifts can be observed in
the covalent CDs-DOX. In both complexes, the bonded DOX peak at 480 nm indicates a redshift
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relative to the pure DOX at 485 nm. The pure FA has an absorption peak at 285nm. From the
FA-CDs-DOX, there is a peak at 255 nm. This peak could be a combinational peak from the
attached FA since this peak cannot be observed in the CDs-DOX. The Uv-vis spectra of the
covalent FA-CDs-DOX and CDs-DOX confirm the successful fabrication of the complexes.
82,37,81

2

CDs-GEM

1.8

FA-CDs-GEM

1.6

CDs
GEM

Absorbance

1.4

FA

1.2
1
0.8
0.6
0.4
0.2
0
190

240

290

340

390
440
Wavelength/nm

490

540

590

Figure 11. UV-vis spectra of obtained CDs (0.01mg/ml), CDs-GEM (0.01mg/ml), and
0.01mg/ml FA-CDs-GEM complex. The insert shows fluorescence spectra of CDs, CDs-GEM
and FA-CDs-GEM excited at 360 nm.
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The FA-CDs-GEM and the CDs-GEM covalent complexes maintained the two UV-vis
absorption peaks of the attached CDs at 240 nm and 344 nm as seen in figure 11. In the CDGEM complex, there is a blue shift of characteristic CDs peak from 198 nm to 204 nm. Also, the
peak at 240 nm is the blue shift of one of GEM's typical peaks at 236 nm. A typical pure FA
peak occurs at 285nm. In the FA-CDs-GEM, there is a small peak at 250nm which can be
observed when zoomed out. This peak is absent in the CDs-GEM. Therefore, this peak might be
a blue shift peak of the FA confirming the successful formation of the FA-bound complex. The
presence of the absorption peaks 204 nm, 240 nm, and 344 nm for CDs, and the absorption peak
of the GEM at 269 nm on the complex shows successful fabrication.
Photoluminescence Analysis of Nanoparticle
Another optical property of the nanoparticles that is vital to their application in biological
research, specifically in bioimaging is photoluminescence (PL). The PL characteristic of CDs
solution was observed at different excitation wavelengths from 300 nm to 390 nm, with 10 nm
increment as seen in figure 12. The PL spectra of the CDs presented an excitation-dependent
emission behavior. The PL intensity increased progressively from excitation of 320 nm to 360
nm and started to decrease beyond the excitation at 360 nm. This excitation-dependent PL
property exhibited by the CDs solution is useful in multicolor biological imaging.36,82
Concerning the fluorescence spectra, the maximum excitation, and emission wavelengths were
respectively found at 360 and 450 nm as already reported.36,33 The UV-vis properties and the
fluorescent behavior of CDs are attributed to the electronic surface band structure which also
affects the energy bandgap of the CDs.
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Figure 12. FL spectra of CDs (0.01 mg/mL). The inset at the upper-right corner shows a
photograph of D.I water (left), and CDs in an aqueous solution (right) under visible light

In Figure 13A and 13B respectively for CDs-DOX and FA-CDs-DOX, both NPs
exhibited distinct emission peak at 450 nm (λex= 360 nm) as CDs. Compared the emission peak
intensity, the trend is CDs > FA-CDs-DOX > CDs-DOX. According to Hong Et al.36, the
decrease of the emission intensity might be as a result of the attached DOX. That is, the DOX
might have slightly quenched the CDs emission. The drop in the intensity might indicate
successful fabrication of DOX to the CDs.36 Moreover, the blue color of the CDs-DOX is much
brighter than the solution of FA-CDs-GEM. this difference in the emission might be due to the
presence of the FA. This and the decrease in the emission intensity in the FA-CDs-DOX
complex might be contributed by the attached FA.
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Figure 13. FL spectra of 0.01mg/mL covalent DOX complexes
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CDs – DOX (A)and 0.01mg/mL FA – CDs – DOX (B) at different excitation wavelength (300
nm – 390 nm). The insert photograph is the solution of the complex under UV light.
Similar fluorescent behavior was observed in the NPs with anticancer drug GEM as seen
in figure 14A and 14B That is, the emission intensity increased gradually from excitation of 320
nm to 360 nm and started decreasing after 360 nm. Again, the highest emission intensity
occurred at 450 nm when the excited at 360 nm. These trends are similar to the fluorescence
behavior of the CDs. For the FA-CDs-GEM complex, when it was excited at 310 nm, 390 nm,
380 nm, the emission intensity shifted to around 500 nm is presented in figure 14B. This change
explains why the FA-CDs-GEM complex appears greenish under UV light. This shift is observed
as an emission redshift. A similar observation was seen in the CDs-GEM when it was excited at
380 nm and 390 nm. This phenomenon was also reported by Liyange Et al.72 This redshift is a
result of the differences in energy levels associated with the various surface state formed by
distinct chemical groups on the FA-CDs-GEM and the CDs-GEM surface.83,71 However, the
CDs-GEM solution under UV light shows a similar color as the pure CDs. The difference in the
color of the FA-CDs-GEM and the CDs-GEM might be as a result of the FA bounded to the
complex. The redshift, difference in solution color, and the reduction in peak intensity in both
FA-CDs-GEM and CDs-GEM could further confirm the successful formation of GEM
complexes.15,36,41
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Figure 14. FL spectra of 0.01mg/mL covalent GEM complexes.
CDs-GEM (A) and 0.01 mg/mL of FA-CDs-GEM (B) excited from 300 nm – 390 nm. The inset
at the upper-right corner shows a photograph of CDs-GEM (A) and FA-CDs-GEM (B) in an
aqueous solution (right) and D.I water (left) under visible light.
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FTIR for Nanoparticle
The chemical groups present on the surface of the NPs were determined by FTIR. The
FTIR spectrum for CDs in figure 15 shows predominant peaks occurring at 3228 cm-1, 1651 cm1

, 1539 cm-1 and 1045 cm-1. The absorption bands at 3228.8 cm−1 corresponded to O-H stretching

vibrations in carboxylic acid or N-H stretch vibration in primary NH2. The N-H bending
vibration is observed around 1651 cm−1, which is overlayed by the peaks of the carbonyl
functional group (C=O) on the CDs surface.71 The bands appearing at 1045 cm−1 can be assigned
to C-O-C in stretching bond. The absorption peaks suggest the presence of carboxylic acid,
hydroxyl groups, and amine functional groups. These characteristic peaks of the CDs are
consistent with reports by Yuan Et al.82 These functional groups contribute to the high-water
solubility of CDs.

Figure 15. ATR-FTIR spectra of CDs
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Figure 16. ATR-FTIR spectra of FA
The IR of pure FA has distinctive peaks at 3546 cm-1(strong, O-H), 3415cm-1 (weak, of C-H),
and 1653 cm-1 (strong, C=O vibration).84
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Figure 17. ATR-FTIR spectra of pure DOX
The broad peak at 33940 cm-1 (strong and broad, O-H/N-H stretch), peak at 2939cm-1 (weak, CH), 1724cm-1 (strong, C=O bond) 1616 cm-1 and 1581 cm-1 (strong, C=O and N-H), 1581 cm-1
(strong, N-H), 1284 cm-1 (strong, C-O-C), 1118 cm-1 (strong, C-O in secondary alcohol) and
1014 cm-1 (strong, C-O in primary alcohol).85
In the covalent CDs-DOX FTIR spectrum in figure 18, there are predominant peaks at
3317 cm-1, 2970 cm-1, 1705 cm-1, 1643 cm-1, 1610 cm-1, and 1076 cm-1. The broad and strong
peak around 3317cm-1 represents the amide -NH2 vibration peak in the covalent CDs-DOX. The
strong peak at 1643 cm-1 shows the presence of primary amide N-H bending while the peak at
1705cm-1 represents amide C=O stretch.37 These two peaks are absent in the pure CDs but are
week in the pure DOX and FA spectra.
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Figure 18. ATR-FTIR spectrum of covalent CDs-DOX comp
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Figure 19. ATR-FTIR spectrum of covalent FA-CDs-DOX (A) and noncovalent FA-CDs-DOX
complex (B)
In the covalent FA-CDs-DOX FTIR spectrum in figure 27A, the predominant peaks are
at around 3348 cm-1, 1643 cm-1, and medium peak at 1200 and 1080 cm-1. Compared to CDs, the
peak around 3348 cm-1 is much stronger, which may represent the vibration -NH2 in amides. The
broad and strong peaks occurring at 1643 cm-1 that overlaps 1700 cm-1 correspond to C=O bond
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stretching in amide bond 42 and amide primary -NH2 bend. The peak at 1643 cm-1 in the covalent
complex is stronger than the NH2 bending peak found in pure CDs, FA and DOX. This could be
as a result of various amide bonds formed on different sites of the CDs surface confirming the
covalent attachment of the FA, and DOX to the CDs.33 The characteristic peaks at 1234.44cm-1
and 1481 cm-1 show the presence of C-N stretching vibration in typical amide bonds.86 This peak
is also stronger in the covalent complex and very weak in the pure samples (CDs, FA, and
DOX). Such peak is also much stronger in FA-CD-DOX than in CDs-DOX covalent complex, it
can be implied that the bond formed occur with FA and DOX both, than just with DOX alone.
The peaks of C=O, C-N, and C(O)N-H in the FA-CDs-DOX spectrum further indicate the
covalent bonding between FA-CDs and CDs-DOX.82
The FTIR spectra for the noncovalent FA-CDs-DOX show very different peak
characteristics compared to covalent FA-CDs-DOX. In the noncovalent FA-CDs-DOX in figure
19B, the peaks around 3300 cm-1 representing the O-H bond in the carboxylic acid group There
may be few amide groups, the -NH2 in amide peak may be covered by the -OH group peak. The
peak around 1200cm-1 in the noncovalent complex spectra is much weaker, which indicates the
C-N bond is much less in the noncovalent complex. All the above data in the IR spectrum of the
covalent complex confirm the successful synthesis of the covalent series.
FTIR for GEM Nanoparticle
FTIR spectra for CDs-GEM and FA-CDs-GEM show similar peaks as seen in figure 21A
and 27B respectively. The broad and strong peaks at 3352.28 cm-1 and 3275.13 cm-1 show the
presence of -OH and -NH2 in amide stretch. The peaks are broader than in several -OH peaks in
the pure GEM. The new peaks at 1697 in cm-1 in both complexes show carbonyl group in the
amide bond.43,87 The strong peak at 1728 cm-1 in GEM does not show up in the IR spectra of
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another two complexes. Instead, the multiple strong peaks around 1635 cm-1 and 1647 cm-1 may
be due to the overlay of the -C=O bond and -N-H bending in amides.36 The broad peak around
1200 cm-1 may be the characteristic peaks of C-N stretch vibration in amide bond, which is
comparable stronger in FA-CDs-GEM complex.15,40 This C-N peak is very week in CDs, FA,
and pure GEM. This peak might be a new bond form during the covalent synthesis of two
covalent complexes.

Figure 20. ATR-FTIR spectra of pure GEM
The narrow and weak peak at 3410 cm-1 (strong and narrow for O-H vibration) and 3010 cm-1
(weak, O-H) The peak at 1728 cm-1 (strong and broad, C=O).
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Figure 21 (continued on the next page)
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Figure 21. ATR-FTIR spectra of CDs-GEM (A) and FA-CDs-GEM (B)

Drug Loading Profile
One of the most appreciable properties of CDs is the presence of different chemical
groups on the CDs surface. This makes the CDs undergo different reactions with other chemical
compounds like DOX. The noncovalent attachment of drugs to CDs is usually reported with a
high drug loading efficiency than when drugs are attached via covalent. However, there is
limited reports on the DLE % and DLC % from the covalent attachment of DOX to CDs. The
DLE % and the DLC % for our prepared noncovalent FA-CDs-DOX were calculated to be
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83.8% and 3.9% respectively while the new covalent FA-CDs-DOX 71% and 80% respectively.
The DLE % and the DLC % for the noncovalent CDs-DOX were also found to be 75% and
7.03% respectively. However, in the covalent CDs-DOX, the DLE% and the DLC% were
calculated to be 53.7 % and 60 % with the DLE% consistent with a similar by Yang Et al.84 that
reported 52.8% for DLE%. Even though the loading efficiency in the covalent series is
relatively low, the loading content is much higher. According to Shen Et al.,88 the changes in the
chemical, physical, and chemical properties during processes like covalent bonding result in
nanocarriers with high drug loading content which is difficult to achieve during electrostatic drug
interactions. The higher DLC might be due to the increase in the space capacity of the CDs
enhanced by the covalent synthesis.88 The DLE and the DLC for covalent FA-CDs-GEM were
reported to be 69.6% and 37.8% respectively while for CDs–GEM was also calculated to be
75.1% and 46.9%. The calculation of the DLE % and DLC % was based on equation 1. Even
though the DLE in the noncovalent series is higher than in the covalent series, the DLC % on the
CDs is lower. The relatively higher DLC % in the covalent series might be a result of the
attachment of the drug via covalent bonding. The drug loading analysis shows that the DOX
covalent complexes have high DLE% and DLC% than in the GEM complex.
pH-sensitive Drug Release For Noncovalent FA-CDs-DOX
To explore the drug release profile of the complex, 2.0 mL of the complex was dialyzed
in MWCO = 1.0 KDa dialysis tube against 100 mL phosphate-buffered saline (PBS) at pH 7.4
for 72 hours. The same setup was done for a pH of 5.0. In some hour’s intervals (1 hr, 2hrs, 4
hrs, 7 hrs, 12 hrs, 22 hrs, 22 hrs 46 hrs, and 72 hrs), 1.0 mL of the release medium was taken and
replaced with an equal volume of the buffer. The UV – vis analysis was done on the collected
released medium where the absorbance at 485 nm represented the released DOX. The

59

concentration of the sample was calculated using the DOX calibration curve to determine the
concentration DOX. The amount of drug in the released medium was determined using excel
with the formula below. The same procedure was followed with the GEM complex. However, in
this step, absorbance at 269nm of the free GEM was recorded for the calculation.
Amount of drug = Concentration (mg/mL) × Volume of medium (mL) × dilution factor.
% cumulative drug release (CDR) = amount of drug (mg) / theoretical drug amount (mg) ×
100.76,81
In an effect to mimic the cancer cell environment and the environment of a healthy cell,
two PBS solutions of different pH were prepared to monitor the drug release behavior of the
nanoparticles. For the pH-dependent DOX release test shown in figure 22, the noncovalent FACDs-DOX solutions released the highest amount of the bonded DOX at pH 5.0 (72.5% at 72 hrs)
than at 7.4 (22.7% after 72 hrs). This signifies that the noncovalent FA-CDs-DOX complexes
can specifically release the DOX into low pH environments.
It is reported that most solid tumors such as human breast cancer cells have low pH of 5.0
while the physiological environments have a pH of 7.4. This property of the noncovalent FACDs-DOX is a desirable advantage in enhancing the efficiency of cancer chemotherapy. From
figure 22, the DOX was released started around 10 hours and up to 72 hours. These two
properties indicate that the noncovalent FA-CDs-DOX has the capacity for selective DOX
release and the possibility to provide prolonged DOX release resulting in an extended period for
therapeutic effect.
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Figure 22. Graph showing the drug released in vitro at regular intervals at pH 5.0 and 7.4
phosphate-buffered saline (PBS)

However, in the covalent FA-CDs-DOX complex relatively low amount of the DOX was
released as seen in figure 23. The highest quantity of DOX release after 72 hours was 44.9% at a
pH of 5.0 and 16.3% at a pH of 7.4. The drug release from this complex is also moderate unlike
observed in the nonvalent FA-CDs-DOX. The moderate release might be due to the strong and
stable covalent bond formed between the DOX and the CDs. This low drug releases the DOX is
due to the strong and stable covalent bond in the complex. The effective drug release may
through other ways, such as enzyme, ligan exchange, photo-induced drug release, bond
reduction, and thermal bond breakage.25
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Figure 23. Graph showing the in vitro DOX released at regular intervals at pH 5.0 and 7.4
phosphate-buffered saline (PBS)
A similar trend as noncovalent FA-CDs-DOX was seen in the covalent FA-CDs-GEM in
figure 24, where the higher quantity of the GEM was release in the acidic condition than in the
slightly alkaline condition. The highest GEM release after 72 hours was 44.2% at pH of 5.0 and
26.5% at pH of 7.4 as depicted in figure 24. The results showed a good specificity of the FACDs-GEM complex for cancer cells with lower pH.

62

FA-CDs-GEM

50

CDR%

40
30
20

CDR (%) pH 5
CDR (%) pH 7.4

10

0
0

10

20

30

40
Time/hrs

50

60

70

80

Figure 24. Graph showing the in vitro GEM released at regular intervals at pH 5.0 and 7.4
phosphate-buffered saline (PBS)
Cell Viability Assay
To investigate the efficacy of the as-prepared complexes on the tumor cells, in vitro
viability test was conducted. In this study, a severe human breast cancer cell line MDA-MB-468
was used. The viability studies were conducted using Alamar Blue assay. In this analysis, the
fluorescence is directly proportional to cell quantity. Therefore, the cell viability was calculated
from the equation: (A treatment − Ablank)/(A control − Ablank) × 100%. In the equation, A is
the absorbance at 590 nm, A treatment is the absorbance of the cell line with drugs/complex, A
blank is the absorbance of the media, A control is the absorbance of the cell line without any
treatment. 89,90 The cell viability of pure DOX, covalent, and noncovalent FA-CDs-DOX against
the MDA-MB468 cell lines is shown in Figures 25 and 26. In figure 25, the cell viability with the
free DOX with respect to the DOX complexes was lower at all the exposure concentrations.
According to the data, the noncovalent FA-bound complex had higher efficacy toward the MDA63

MB468 cells than the covalent complexes. This observation might be due to the low release rate
of the DOX from the strong stable amide bond in the covalent complex. In all the FA bounded
complexes and the covalent CDs-DOX, considerably high cell death was observed than in the
noncovalent CDs-DOX. The FA bounded complexes will be much preferred since the FA can
help target the cancer cells than healthy cells. The viability test on the MDA-MB-468 suggests
that all the FA bounded complexes can potentially be used as a drug candidate for invasive breast
cancers such as MDA-MB-468.
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Figure 25. Cell viability of MDA-MB-468 cells exposed to free DOX, noncovalent CDs-DOX,
and noncovalent FA-CDs-DOX at 72 h
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Figure 26. Cell viability of MDA-MB-468 cells exposed to free DOX, covalent CDs-DOX, and
covalent FA-CDs-DOX at 72 h

65

CHAPTER 4. CONCLUSION

I successfully prepared covalent and noncovalent FA-CDs-DOX and covalent FA-CDsGEM. Also, the UV-vis, fluorescence, and IR spectra for the CDs, FA, covalent and noncovalent
FA-CDs-DOX, and the covalent FA-CDs-GEM were compared to confirm the successful
fabrication of NPs complexes. According to the data from VT, the sizes of all NPs synthesized is
between 2 nm and 5 nm. The in vitro drug release data show that the noncovalent FA-CDs-DOX
can efficiently release the drug in acidic conditions than in the covalent series. The covalent FACDs-GEM had relatively moderate drug release in the acidic environment. The drug loading
profile shows high DLC in both covalent FA-CDs-GEM and FA-CDs-DOX complexes than the
noncovalent series of FA-CDs-DOX. However, there is higher DLE in the noncovalent series
than in all the covalent complexes. The cell viability against MDA-MB468 cancer cells proved
both covalent and non-covalent FA-CDs-DOX are more specific than the NPs without FA. More
cell viability test is being done by our collaborators from the pharmaceutical department at
ETSU and Xavier University at Louisiana. For further studies, the cytotoxicity of the complexes
on different types of cancer cell lines will be explored. We will investigate other methods of
attaching the DOX/GEM to the CDs. We will then consider preparing FA-CDs-based
combinational chemotherapy (DOX and GEM) – the possibility to increase the overall
therapeutic effect.
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APPENDICES
Appendix A: Standard Calibration and Drug Release Tables

Table 4. Different Concentration/mg/mL of DOX and Absorbance Taken at 485nm
Concentration (mg/mL)

Absorbance

0.075

1.486

0.05

1.074

0.025

0.51

0.01

0.141

0.005

0.053

0.001

0.002

Blank

0
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Table 5. Different Concentrations of GEM.HCl and Absorbance Measured at 269 nm
Concentration (mg/mL)

Absorbance at 268 nm

0.03

2.624

0.02

1.694

0.01

0.87

0.003

0.464

0.002

0.241

0.001

0.088

0

0
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Table 6. The Concentration of DOX and the Cumulative Drug Release (CDR) in Dialysis
Medium from Noncovalent FA-CDs-DOX at pH 5.0
Sr No. Time (hrs.) Abs (A) Conc. (mg/ml) Amt. (mg) CDR (%) pH 5.0
1

1

0.006

0.00145

0.145

14.51

2

2

0.021

0.00218

0.218

21.76

3

4

0.042

0.00319

0.319

31.92

4

7

0.045

0.00334

0.334

33.37

5

12

0.057

0.00392

0.392

39.18

6

22

0.066

0.00435

0.435

43.53

7

46

0.081

0.00508

0.508

50.78

8

72

0.126

0.00726

0.726

72.55
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Table 7. The Concentration of DOX and the Cumulative Drug Release (CDR) in Dialysis
Medium from Noncovalent FA-CDs-DOX at pH 7.4
Sr No. Time (hrs.) Abs (A) Conc. (mg/ml) Amt. (mg) CDR (%) pH 7.4
1

1

0.001

0.00121

0.121

12.09

2

2

0.006

0.00145

0.145

14.51

3

4

0.01

0.00164

0.164

16.44

4

7

0.012

0.00174

0.174

17.41

5

12

0.016

0.00194

0.194

19.35

6

22

0.017

0.00198

0.198

19.83

7

46

0.019

0.00208

0.208

20.80

8

72

0.023

0.00227

0.227

22.73
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Table 8. The Concentration of DOX and the Cumulative Drug Release (CDR) in Dialysis
Medium from Noncovalent FA-CDs-DOX at pH 7.4

Sr No. Time (hrs.) Abs (A) Conc. (mg/ml) Amt. (mg) CDR (%) pH 7.4
1

1

0.015

0.00074

0.0740

7.40

2

2

0.035

0.00130

0.1294

12.95

3

4

0.038

0.00138

0.1378

13.78

4

7

0.046

0.00160

0.1599

15.99

5

12

0.047

0.00163

0.1627

16.28

6

22

0.06

0.00199

0.1987

19.88

7

46

0.073

0.00235

0.2348

23.48

8

72

0.084

0.00265

0.2653

26.53
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Appendix B: Calculation of DLE and DLC Before Dialysis
Example of Noncovalent CDs-DOX
2.5

Absorbance

2
1.5

non-covalent CDs-DOX before dialysis

1
0.5
0
190

290

390
Wavelength/nm

490

Figure 27. UV-vis of noncovalent CDs-DOX before dialysis.
DOX absorbance at 450 nm is 0.075. According to the equation of Y= 20.676X-0.0237, the
concentration of free DOX is 0.0048 mg/mL.
Free DOX after synthesis = 0.0048 𝑚𝑔/𝑚𝑙 𝑥 3.9 𝑚𝐿 = 0.01872𝑚𝑔
Dilution factor (0.2 ml in 5 ml D.I water) = 1/0.2 = 5
Therefore, the mass of free DOX in the diluted sample = 0.01872 𝑚𝑔 ∗ 5 = 0.0936𝑚𝑔
The mass of total DOX for synthesis = 1𝑚𝑙 𝑥 0.4 𝑚𝑔/𝑚𝐿 ∗ 543.52/580 = 0.3748 𝑚𝑔
Therefore, the mass of DOX in conjugation after synthesis = 0.3748 𝑚𝑔 – 0.0936𝑚𝑔 =
0.2812𝑚𝑔
DLE = (0.2812𝑚𝑔/0.3748) ∗ 100% = 75.0%
DLC = 0.28120𝑚𝑔 /4𝑚𝑔 ∗ 100% = 𝟕. 𝟎𝟑 %
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Example of Noncovalent FA-CDs-DOX
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Figure 28. UV-vis of noncovalent FA-CDs-DOX before dialysis.
DOX absorbance at 485 nm is 0.072. According to the equation of Y= 20.676X-0.0237, the
concentration of free DOX is 0.00463 mg/Ml
Dilution factor (0.2 ml in 5 ml D.I water) = 1/0.2 = 5
Therefore, the mass of free DOX after synthesis = 0.00463𝑚𝑔/𝑚𝑙 𝑥 3.9 𝑚𝐿 ∗ 5 = 0.0903𝑚𝑔
The mass of total DOX for synthesis = 1.0345 µ𝑚𝑜𝑙 ∗ 543.52 = 0.5623 𝑚𝑔
Mass of DOX in conjugation after synthesis = 0.5623 𝑚𝑔 – 0.0978 𝑚𝑔 = 0.472 𝑚𝑔
DLE = 0.472 𝑚𝑔 / 0.5623 𝑚𝑔 ∗ 100% = 83.8%
DLC =0.472 𝑚𝑔 /(8𝑚𝑔/𝑚𝑙 ∗ 1.5𝑚𝑙) ∗ 100% = 3.9 %
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Absorbance

Example of Covalent FA-CDs-DOX
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Figure 29. UV-vis of covalent FA-CDs-DOX before dialysis
DOX absorbance at 485 nm is 0.340, According to the equation of Y= 20.676X-0.0237, the
concentration of free DOX is 0.0175 mg/mL.
The dilution factor = 0.2𝑚𝑙/5𝑚𝑙 = 25.
Free DOX after synthesis = 0.0175𝑚𝑔/𝑚𝑙 𝑥 25 𝑥 3 𝑚𝐿 = 1.3125 𝑚𝑔
The mass of total DOX for synthesis = 8.36 𝑢𝑀𝑜𝑙 𝑥543.5𝑔/𝑚𝑜𝑙 = 4.54 𝑚𝑔
Mass of DOX in conjugation after synthesis = 4.54 𝑚𝑔 – 1.3125𝑚𝑔 = 3.2275 𝑚𝑔
DLE = (3.2275 𝑚𝑔/ 4.54) ∗ 100% = 71.0%
DLC =3.32591𝑚𝑔 / (4𝑚𝑔 𝐶𝐷𝑠 + 0.013𝑚𝑔 𝐹𝐴) ∗ 100% = 80 %
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Example of Covalent CDs-DOX
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Figure 30. UV-vis of covalent CDs-DOX before dialysis.
DOX absorbance at 485 nm is 0.582. According to the equation of Y= 20.676X-0.0237, the
concentration of free DOX is 0.029mg/mL
Free DOX after synthesis = 0.029 𝑚𝑔. 𝑚𝑙 𝑥 2.9 𝑚𝐿 = 0.0841 𝑚𝑔
Dilution factor (0.2 ml in 5 ml D.I water) = 5/0.2 = 𝟐𝟓
Therefore, the mass of free DOX in the diluted sample = 0.0841 𝑚𝑔 ∗ 25 = 𝟐. 𝟏𝟎𝟐 𝒎𝒈
The mass of total DOX for synthesis = 8.36𝑢𝑚𝑜𝑙 𝑥543.5𝑔/𝑚𝑜𝑙 = 4.54 𝑚𝑔
Mass of DOX in conjugation after synthesis = 4.54 𝑚𝑔 – 2.102 𝑚𝑔 = 𝟐. 𝟒𝟑𝟖 𝒎𝒈
DLE = (2.438/ 4.54) ∗ 100% = 53.7%
DLC =2.8853𝑚𝑔/ (4𝑚𝑔 𝐶𝐷𝑠) ∗ 100% = 𝟔𝟎. 𝟗 %
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Figure 31. UV-vis of covalent CDs-GEM before dialysis.
GEM.HCl absorbance at 269 nm is 0.634. According to the equation of Y= 83.637X-0.0608, the
concentration of free GEM.HCl is 0.00831 mg/mL
Free GEM.HCl after synthesis = 0.00831𝑚𝑔/𝑚𝐿 ∗ 3𝑚𝐿 ∗ 25 = 0.6231 𝑚𝑔
The mass of GEM.HCl after synthesis = 5 𝑚𝑔/𝑚𝑙 𝑥 0.5 𝑚𝐿 = 𝟐. 𝟓 𝒎𝒈
Mass of GEM.HCl in conjugation after synthesis = 2.5 𝑚𝑔 – 0.6231𝑚𝑔 = 1.8769 𝑚𝑔
DLE = 1.8769 𝑚𝑔/ (5𝑚𝑔/𝑚𝑙 ∗ 0.5𝑚𝑙) ∗ 100% = 75.1
Mass of CDs used in the synthesis = 4 mg
DLC =1.8769 𝑚𝑔/ (4) = 46.9 %
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Example of Covalent FA-CDs-GEM.
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Figure 32. UV-vis of covalent FA-CDs-GEM before dialysis.
GEM absorbance at 269 nm is 0.68. According to the equation of Y= 83.637X-0.0608., the
concentration of free GEM.HCl is 0.00982 mg/mL
Free GEM after synthesis = 0.00886 𝑚𝑔/𝑚𝐿 ∗ 3 𝑚𝐿 ∗ 25 = 𝟎. 𝟔𝟔𝟒 𝒎𝒈
The mass of GEM.HCl after synthesis = 5 𝑚𝑔/𝑚𝑙 𝑥 0.5 𝑚𝐿 = 2.5 𝑚𝑔
Mass of GEM after synthesis (when HCl is no more bonded to GEM) = 8.3µ𝑀𝑜𝑙 ∗
263.2𝑚𝑔/𝑚𝑜𝑙𝑒 = 𝟐. 𝟏𝟖𝟒 𝒎𝒈
Therefore, the mass of GEM in conjugation after synthesis = 2.184 𝑚𝑔 – 0.664 𝑚𝑔 =
𝟏. 𝟓𝟏𝟗𝟕 𝒎𝒈
DLE = 1.5197𝑚𝑔/ (2.184 𝑚𝑔) ∗ 100% = 69.6%
Mass of CDs used in the synthesis = 4 mg
Mass of folic acid used for the synthesis = 0.013 mg
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The total mass of FA and CDs = 4.013 mg
DLC =1.5197𝑚𝑔/4.013 ∗ 100 = 𝟑𝟕. 𝟖%
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